Anti-angiogenic therapy for diabetic macular edema



Cite item

Full Text

Abstract

Diabetic retinopathy remains one of the greatest challenges for healthcare system worldwide despite the fact that the incidence of visual acuity impairment in diabetic population has decreased due to examination quality improvement and dynamic observation of patients. Visual acuity impairment in diabetic patients is often related to diabetic macular edema. Laser photocoagulation has been regarded as gold standard for diabetic macular edema all over past years. Nevertheless laser photocoagulation provides vision acuity stabilization rather than improvement. Since early 2000s pharmacological approach of this severe disease has been established. As vascular endothelial growth factor is one of the crucial factors that is involved in the pathogenesis of diabetic retinal disorders, VEGF inhibitors are now recognized as a treatment of choice for diabetic macular edema. This article considers results of different clinical trials that were investigating anti-VEGF therapy efficacy in DME treatment.

About the authors

Fedor Shadrichev

Saint-Petersburg regional diabet care center;
Pavlov first Saint-Petresburg state medical university

Email: shadrichev_dr@mail.ru

ph.d.; chief of ophthalmology deparment; assistant

Russian Federation, 194354 Saint-Petersburg, Sikeyros str, 10; 197022 Saint-Petersburg, L.Tolstogo str, 6/8

Nyurguyana N. Grigor'eva

Saint-Petersburg regional diabet care center;
Saint-Petersburg state university

Author for correspondence.
Email: grinur@mail.ru
ORCID iD: 0000-0002-3877-2474
SPIN-code: 7299-4748
ResearcherId: M-5920-2015

ph.d; ophthalmologist; assistant of department of otorinolaringology and ophthalmology

Russian Federation, 194354 SPb, Sikeyros str, 10; 199106 SPb, VO, 21 line, 8a    

Elizaveta Rozhdestvenskaya

City multifield hospital №2

Email: shorie48@gmail.com

doctor

194354 Saint-Petersburg, Uchebnii per, 5

References

  1. Global report on diabetes. Женева: Всемирная организация здравоохранения; 2018, 88с. Лицензия: CC BY-NC-SA 3.0 IGO.
  2. International Diabetes Federation. Atlas of diabetes. 2017. – (8-th edition) – 150p
  3. Lee R., Wong TY., Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss // Eye Vis (Lond). – 2015. – Vol. 2. – P. 17
  4. Zheng Y., He M., Congdon N. The world epidemic of diabetic retinopathy// Indian J Ophthalmol. – 2012. – Vol. 60. – N.5. – P.428-31.
  5. Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. // Eye (Lond). – 2015. – Vol.29. – P.1115-1130.
  6. Miller K, Fortun JA. Diabetic macular edema: current understanding, pharmacologic treatment options and developing therapies. // Asia-Pac J Ophthalmol. – 2018. – Vol.7. – P.28-35.
  7. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. // J Diabetes Res. – 2016. – Vol.2016. – 17 p.
  8. Beaulieu W.T, Bressler N.M., Melia M. et all. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial // Am J Ophthalmol. – 2016. – Vol.170. – P. 206–213.
  9. Duh E.J., Sun J.K., Stitt A.W. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies // JCI Insight. – 2017. – Vol.2 (14). – e93751.
  10. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F. et al., Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). // Ophthalmologica. – 2017. – Vol. 237 (4). – P. 185-222.
  11. Ogata N, Wang L, Jo N, et al. Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury. // Curr Eye Res. – 2001. – Vol.22. – P.245-252.
  12. Simo R, Hernandez C, European Consortium for the Early Treatment of Diabetic Retinopathy. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. // Trends Endocrinol Metab. – 2014. – Vol.25. – P.23-33.
  13. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. // Arch Ophthalmol. – 1985. – Vol. 103 (12). – P.1796-1806.
  14. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness // World J Diabetes. – 2011. – Vol. 2 (6). – P.98-104.
  15. Bahrami B., Hong Th., Gilles M.C. et all. Anti-VEGF Therapy for diabetic eye diseases. // Asia-Pac J Ophthalmol. – 2017. – Vol. 6. – P.535-545.
  16. Ferrara N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene // Nature. – 1996. –Vol. 380 (6573). – P. 439–42.
  17. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. // Kidney International. – 1999. – Vol. 56. – P. 794-814.
  18. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. // Eur. Cytokine Netw. – 2009. –Vol. 20 (4). – P. 158-63.
  19. Freedman S.B., Isner J.M. Therapeutic Angiogenesis for Coronary Artery Disease. Review. // Ann.Intern.Med. – 2002. – Vol.132. – P. 54-71
  20. Jin K, Zhu Y, Sun Y. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. // Proc Natl Acad Sci U S A. – 2002. – Vol. 99 (18). – P.11946-50.
  21. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. // Clin Sci. – 2005. – Vol. 109. – P. 227-241.
  22. Wang J, Xu X, Elliott MH, et al. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. // Diabetes. – 2010. – Vol.59. – P. 2297-2305.
  23. Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. // Invest Ophthalmol Vis Sci. – 2002. – Vol.43. – P.849-857.
  24. Zhang X, Bao S, Lai D, et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. // Diabetes. – 2008. – Vol.57. – P.1026-1033.
  25. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. // Angiogenesis. – 2012. – Vol. 15 (2). – P.171-185.
  26. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. // N Engl J Med. – 1994. – Vol.331. – P.1480-1487.
  27. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. // Ophthalmology. – 2006. – Vol. 113. – P.294-301.
  28. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. // Nat Med. – 2003. – Vol.9. – P.936-943.
  29. Bry M, Kivelä R, Leppänen VM. Vascular endothelial growth factor-B in physiology and disease. // Physiol Rev. – 2014. – Vol.94 (3). – P.779-94.
  30. Nguyen QD, De Falco S, Behar-Cohen F, et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. // Acta Ophthalmol. – 2016.
  31. Kovacs K, Marra KV, Yu G, et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. // Invest Ophthalmol Vis Sci. – 2015. – Vol. 56. – P.6523-6530.
  32. Kinoshita S, Noda K, Saito W, et al. Vitreous levels of vascular endothelial growth factor-B in proliferative diabetic retinopathy. // Acta Ophthalmol. – 2016. – Vol.94. – P.521-523.
  33. Zhong X, Huang H, Shen J, et al. Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. // Mol Vis. – 2011. – Vol.17. – P. 492-507.
  34. Bressler N.M., Beck R.W., Ferris F.L. 3rd. Panretinal photocoagulation for proliferative diabetic retinopathy. // N Engl J Med. – 2011. – Vol. 365. – P.1520-1526.
  35. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. // Ophthalmology. – 1981. – Vol.88. – P.583-600.
  36. Duh E.J., Yang H.S., Suzuma I. et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. // Invest Ophthalmol Vis Sci. – 2002. – Vol.43. – P.821-829.
  37. Hattenbach LO, Beck KF, Pfeilschifter J, et al. Pigment-epithelium-derived factor is upregulated in photocoagulated human retinal pigment epithelial cells. // Ophthalmic Res. – 2005. – Vol. 37. – P.341-346.
  38. Ogata N, Ando A, Uyama M, et al. Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. // Graefes Arch Clin Exp Ophthalmol. – 2001. – Vol.239. – P.87-95.
  39. Freund K. B., Korobelnik J., Devenyi R. Treat-and-extend regimens with anti-VEGF agents in retinal diseases. // Retina. – 2015. – Vol. 35. – Issue 8. – P.1489–1506.
  40. Lanzetta P, Loewenstein A. Fundamental principles of anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases // Graefes Arch Clin Exp Ophthalmol. – 2017. – Vol. 255. – P.1259-1273.
  41. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study// Diabetes Care. – 2010. – Vol. 33. N. 11. – P. 2399-405.
  42. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema // Ophthalmology. – 2011. – Vol.118. – N. 4. – P. 615-625.
  43. Nguyen QD, Brown DM, Marcus DM, et al., Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. // Ophthalmology. – 2012. – Vol. 119. – P. 789-801.
  44. Brown D.M., Schmidt-Erfurth U, Do DV et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. // Ophthalmology. – 2015. – Vol. 122. – P. 2044–2052.
  45. Heier J.S., Korobelnik J.F., Brown D.M., et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. // Ophthalmology. – 2016. – Vol.123. – N.11. – P. 2376–85.
  46. Korobelnik J-F., Do D.V., Schmidt-Erfurth U., et al. Intravitreal aflibercept for diabetic macular edema. // Ophthalmology. – 2014. – Vol. 121. – N.11. – P.2247-54.
  47. Wells JA., Glassman AR., Ayala AR., et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. // N Engl J Med. – 2015. – Vol. 372. – N. 13. – P.1193-1203.
  48. Wells JA., Glassman AR., Ayala AR., et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. // Ophthalmology. – 2016. – Vol. 123. – P.1351-1359.
  49. Jampol L.M., Glassman A.R., Bressler N.M. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. // .JAMA Ophthalmol. – 2016. – Vol. 134 (12).
  50. Bressler SB, Liu D, Glassman AR et al. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. // JAMA Ophthalmol. – 2017. – Vol. 135. – N. 6. – P.558-568.
  51. Bressler S.B., Glassman A., Almukhtar T. et al. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema // American journal of ophthalmology. – 2016. – Vol.164. – P. 57-68.
  52. Elman MJ., Bressler NM., Qin H., et al. Expanded 2-year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. //Ophthalmology. – 2011. – Vol.118. – N. 4. – P.609–614.
  53. Elman MJ., Aiello LP., Beck RW., et al. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. // Ophthalmology. – 2010. – Vol.117. – P.1064–1077.
  54. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year Randomized Trial Results. // Ophthalmology. – 2012. – Vol.119 (11). – P.2312-2318.
  55. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. // JAMA Ophthalmol. – 2018. – Vol.136. – N. 3. – P.257-269.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Shadrichev F., Grigor'eva N.N., Rozhdestvenskaya E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-65574 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies